Mechanism of anticoagulation therapy for non-small cell lung cancer
10.3969/j.issn.1000-8179.2016.04
- VernacularTitle:抗凝对非小细胞肺癌治疗的机制研究
- Author:
Minting MA
;
Chengyuan LIU
;
Suju WEI
- Publication Type:Journal Article
- Keywords:
malignant tumor;
high coagulation mechanism;
anticoagulant therapy;
non-small cell lung cancer
- From:
Chinese Journal of Clinical Oncology
2016;43(4):173-176
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, a number of studies have focused on malignant tumor patients with coagulant function abnormality, which causes thrombus complications, tumor growth, infiltration of closely related cells, transfer, and so on. These factors directly affect prog-nosis. Heparin is a widely known anticoagulant, and anticoagulation drugs have been included in malignant tumor treatment guide-lines. Ameaican Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and American College of Clinical Pharmacy (ACCP) recommend low-molecular-weight heparin as the first choice for the treatment of cancer thrombosis. However, the prophylactic use of anticoagulant drugs in patients with tumor control disease, as well as the prolonged PFS and OS mechanism, is still unclear. The recently publishedReport of incidence and mortality in China(2012) suggests that lung cancer incidence and mortality ranked first place. This review will introduce several aspects of anticoagulant drugs that can be used to control the recurrence of malig-nant tumor metastasis and prolong the survival mechanism of pathophysiology.
